Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map
Jensterle M, Janez A
Drugs (2026)
Drugs review by the Ljubljana endocrinology group mapping GLP-1RA and dual GIP/GLP-1 RA evidence in polycystic ovary syndrome — liraglutide has the densest PCOS-specific evidence with reproducible weight loss, visceral and hepatic fat reduction, and early signals on androgen and fertility benefits; semaglutide and tirzepatide data remain extrapolative.
This narrative product-segmented review in Drugs by Mojca Jensterle and Andrej Janez at the University Medical Centre Ljubljana — a long-standing PCOS clinical-research group — maps the evidence for incretin-based anti-obesity medications in polycystic ovary syndrome (PCOS). PCOS affects approximately 8–13% of reproductive-age women, is tightly coupled to obesity, visceral adiposity, and insulin resistance, and has limited high-quality pharmacotherapy beyond off-label metformin.
The review structures the evidence across three drug classes — liraglutide, semaglutide, and tirzepatide — and three evaluation domains: mechanistic, clinical, and safety.
Liraglutide has the densest PCOS-specific evidence base. The published trials and cohort studies demonstrate reproducible weight loss across small and heterogeneous PCOS cohorts, reductions in visceral adiposity and hepatic fat, improved glycaemia and inflammatory markers, and preliminary signals for androgen-axis improvement and fertility benefits in selected phenotypes. The trials are small, single-centre, and heterogeneous in entry criteria and outcome assessment, but they converge directionally.
Semaglutide data in PCOS remain sparse but conceptually rich. The available trials demonstrate weight-loss efficacy and mechanistic plausibility, with preliminary signals of increased likelihood of natural conception. The dose-response and durability data are still missing.
Tirzepatide currently has no PCOS-specific trial evidence. Recommendation cannot extend beyond extrapolation from the SURPASS and SURMOUNT obesity-and-diabetes trials.
The authors propose a multidimensional metabolic high-risk PCOS phenotype as the most rational current target for incretin therapy. Across all three agents, the major evidence gaps are reproductive outcomes, periconceptional and pregnancy safety, adolescent use, long-term cardiovascular-kidney-metabolic trajectories, obstructive sleep apnoea, musculoskeletal health, and phenotype-stratified treatment response.
This is a narrative review, not a systematic review or meta-analysis — there is no prespecified search protocol, no formal risk-of-bias assessment for the included literature, and no quantitative pooled estimate. The categorisation of evidence density (liraglutide > semaglutide > tirzepatide) is the authors' synthesis, not the output of a structured grading procedure. The recommendation framework — a metabolic high-risk PCOS phenotype as the target — is the authors' clinical judgement, not a formal guideline recommendation.
The underlying liraglutide PCOS literature is dominated by small single-centre cohorts (typical n = 20–80), short duration (typical 12–26 weeks), and heterogeneous entry criteria — some trials enrol obese PCOS, some enrol normal-weight PCOS, some enrol post-metformin-failure populations. The "reproducible weight loss" headline aggregates across these heterogeneous trials and should be read as direction rather than effect size.
Reproductive outcome evidence is preliminary. Pregnancy and lactation safety of incretin therapy is not established; current label guidance is to discontinue 2 months before planned conception for semaglutide. The fertility-benefit signal must be weighed against this contraindication during the conception window.
The Ljubljana group has long-standing relationships with several incretin manufacturers through their PCOS clinical-research portfolio; the authors' disclosure was not extracted in the abstract-only review.
Abstract-only extraction. Per-trial details, response-rate distributions, and the metabolic-phenotype scoring framework cannot be reproduced from the abstract.
07·Member discussion
No member discussion yet.
Member-only conversation lives here — cycle notes, practitioner commentary, pattern-matching. Be the first paying member to start the thread.